Pharmaceuticals News and Research

RSS

Ariel Pharmaceuticals in-licenses AP-1531 from BTG for acute migraine attacks

Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd.

22 Sep 2011

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate), is effective not only in decreasing tumor size but also in reducing the severity of side effects that often accompany a cancer diagnosis.

22 Sep 2011

Influential leaders hold high-level discussions on biomedical S&T initiatives

Influential leaders from the medical and research communities held high-level discussions on biomedical science and technology (S&T) initiatives at the Office of Naval Research (ONR), Sept. 16.

21 Sep 2011

GI Dynamics introduces EndoBarrier Gastrointestinal Liner in Austria

GI Dynamics, Inc. today announced the launch of the EndoBarrier Gastrointestinal Liner in Austria, the establishment of the first two Centers of Excellence and the treatment of patients at each new Center.

21 Sep 2011

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., today announced an agreement to expand Bristol-Myers Squibb's territorial rights to develop and commercialize the anti-PD-1 antibody known as BMS-936558/ONO-4538, and to create a strategic alliance for the co-development and co-commercialization of ORENCIA in Japan.

21 Sep 2011

CRANN partnership with Merck Millipore on research

CRANN, the Science Foundation Ireland funded nanoscience research institute, based at Trinity College Dublin, has today announced a new commercial partnership worth over €130,000 with Merck Millipore, a biotech and pharmaceutical company based in Cork. As part of the research programmes, CRANN will assist Merck Millipore to further develop the nanostructures of their products’ artificial membranes, that are widely used for medical and diagnostic devices, and to deliver new products with improved membrane performances. Artificial membranes are used in a wide array of products such as lab filtration devices, antibody screening kits and blood typing products.

21 Sep 2011

Berson UV used to treat hospital wastewater prior to discharge

Berson’s medium pressure UV systems are being used in a trial in the Netherlands to treat hospital wastewater prior to discharge. In the trial, UV is applied in combination with hydrogen peroxide (H2O2) to generate OH- radicals in a so-called “Advanced Oxidation Process” (AOP). The very reactive OH- radicals attack the pharmaceutical residues in the wastewater, breaking them down into H2O, CO2 and harmless metabolites.

21 Sep 2011

Obama budget plan includes $320 billion in Medicare, Medicaid cuts over 10 years

The squeeze will be felt by future Medicare recipients, in reduced payments to drug companies and hospitals, and with higher costs to states. And, though many parts of the health sector are grumbling about the proposal, some advocates say the president's vision is less painful than some of the ideas that have recently been on the table.

21 Sep 2011

Matrix receives FDA's tentative approval for novel co-packaged version of HIV/AIDS therapy

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) through the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine / Tenofovir Disoproxil Fumarate Tablets, 300 mg/300 mg, co-packaged with Nevirapine Tablets, 200 mg.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Thermo Fisher Scientific cassette cuts tissue embedding time in half

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific SecureSette, a new cassette for histology laboratories that reduces embedding time by 50 percent. The innovative design of new SecureSette™ cassettes makes embedding extremely simple; tissues are orientated during grossing and the cassette is not opened during embedding. An integral sponge securely holds tissue in place during processing which not only improves orientation, but also reduces the time spent re-embedding incorrectly aligned samples by more than half. The result is a more efficient workflow, higher quality and improved patient safety without the need to purchase additional equipment.

From Thermo Fisher Scientific Inc. 20 Sep 2011

Qualitest recalls birth control pills citing “packaging error”

Alabama-based Qualitest Pharmaceuticals is voluntarily recalling several lots of birth control pills because of a packaging error that could leave women at risk for unplanned pregnancy, the Food and Drug Administration (FDA) announced.

20 Sep 2011

Centrifuge releases new version of Visual Network Analytics solution

Centrifuge Systems, Inc. announced Version 2.5 of its Visual Network Analytics solution (VNA) the first and only thin-client, 100% zero footprint web application that discovers hidden meaning and network relationships from public, cloud, and enterprise information.

20 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

ERWW PR forms Health Buzz Group

Euro RSCG Worldwide PR (ERWW PR) announces the formation of its Health Buzz Group, a global division created in response to growing client interest in big, splashy “wows” from small budgets in quick time frames using traditional and social media to generate momentum.

20 Sep 2011

New York Times examines possible entry into global market of generic drugs for NCDs

The New York Times describes how, as the U.N. begins its meeting on non-communicable diseases (NCDs), Chinese and Indian generic drug makers "say they are on the verge of selling cheaper copies" of costly biotech medications used to treat cancers, diabetes, arthritis and other chronic illnesses.

20 Sep 2011

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.

20 Sep 2011

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

FDA approves Amphastar's ANDA for Enoxaparin Sodium Injection

Watson Pharmaceuticals, Inc. today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths.

20 Sep 2011

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.

20 Sep 2011